CCCC

C 4 Therapeutics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 6/10
  • Value↓ 0/10
C 4 Therapeutics sales and earnings growth
CCCC Growth
Good
  • Revenue Y/Y↓ -36.25%
  • EPS Y/Y↑ 25.17%
  • FCF Y/Y↓ -19.28%
C 4 Therapeutics gross and profit margin trends
CCCC Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -297.80%
  • ROIC 5Y↓ -36.84%
C 4 Therapeutics net debt vs free cash flow
CCCC Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

C 4 Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks